Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including reports of deaths and hospitalizations, while working with the FDA to resolve issues.
Novo Nordisk Posts Solid Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. W
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Weight loss drugs: Regulator reprimands Novo Nordisk over promotion
The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda),
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs, as it reported revenue and operating profit broadly in line with analysts’ expectations. The maker of the blockbuster Ozempic and Wegovy drugs has benefited in recent years from huge demand for its products.
Novo Nordisk Stock Rises After Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 billion. The obesity drug market is currently dominated
healthday4h
Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...
Reuters on MSN23h
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ...
Becker's Hospital Review1h
Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...
Fortune on MSN2d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in Denmark
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.